Qingge XIE, Huichen GUO, Shiqi SUN, Jiangtao MA, Zaixin LIU, Xiangtao LIU

A bicistronic DNA vaccine containing gene of FMDV and bovine IFN-..... can prime humoral and cellular ımmune responses of guinea pigs

The study was conducted to evaluate the immunogenicity and protective efficacy of a DNA vaccine against foot-and-mouth disease virus (FMDV). Genes encoding the P1, 2A, 3C of FMDV O/China99 and bovine IFN-α were cloned into pcDNA3.1 (+) expression vector under CMV promoter and FMDV IRES control, respectively. The recombinant plasmids were administered to guinea pigs by intramuscular injection with mono- or bicistronic expression plasmids and aurintricarboxylic acid (ATA). After 2 sequential vaccinations with plasmid DNA, all of guinea pigs were challenged with 100 ID50 FMDV O/China99. Anti-FMDV antibodies were detected by ELISA and neutralization assay, and the phenotyping of T-cell subpopulation in the peripheral blood were performed by flow cytometry. Vaccination of guinea pigs with mono- or bicistronic expression plasmids induced humoral and cellular immune responses to FMDV antigens. In the challenge test, a part of the animals were protected against the challenge of a virulent virus. This study demonstrates that the delivery of FMDV antigens via bicistronic vectors is feasible. Further experimentation with bicistronic delivery systems is required for the optimization and refinement of DNA vaccines to effectively prime protective immune responses against foot-and-mouth disease (FMD).

PDF

___

1. Barteling, S.J., Vreeswijk, J.: Developments in foot-and-mouth disease vaccines. Vaccine, 1991; 9: 75-88.
2. Beck, E., Strohmaier, K.: Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J. Virol., 1987; 61: 1621–1629.
3. Boyer, J.D., Ugen, K.E., Wang, B., Agadjanyan, M., Gilbert, L., Bagarazzi, M.L., Chattergoon, M., Frost, P., Javadiana, A., Williams, W.V., Rafaeli, Y., Ciccarelli, R.B., McCallus, D., Coney, L., Weiner. D.B.: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med., 1997; 3: 526–532.
4. Hoffman, S.L., Doolan, D.L., Sedegah, M., Wang, R., Scheller, L.F., Kumar, A., Weiss, W.R., Le, T.P., Klinman, D.M., Hobart, P., Norman, J.A., Hedstrom, R.C.: Toward clinical trials of DNA vaccines against malaria. Immunol. Cell. Biol., 1997; 75: 376–381.
5. Jiang, C., Magee, D.M., Cox, R.A.: Coadministration of interleukin 12 expression vector with antigen expressing cDNA enhances induction of protective immunity against Coccidioides immitis. Infect. Immun., 1999; 67: 5848–5853.
6. Le Bon, A., Schiavoni, G., D’Agostino, G., Gresser, I., Belardelli, F., Tough, D.F.: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity, 2001; 14: 461–470.
7 Le Bon, A., Tough, D.F.: Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol., 2002; 14: 432–436.
8. Chinsangaram J.M., Koster, M., Grubman M.J.: Inhibition of Ldeleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J. Virol., 2001; 75: 5498-5503.
9. Hallick, R.B., Chelm, B.K., Gray, P.W., Orozco, E.M. Jr.: Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid isolation. Nucleic Acids Res., 1977; 4: 3055-3064.
10. Glasspool-Malone, J., Steenland, P.R., McDonald, R.J., Sanchez, R.A., Watts, T.L., Zabner, J., Malone, R.W.: DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. J. Gene Med., 2002; 4: 323-332.
11. Martínez-Salas, E.: Internal ribosome entry site biology and its use in expression vectors. Curr. Opin. Biotechnol., 1999; 10: 458–464.
12. de Felipe, P.: Polycistronic viral vectors. Curr. Gene Ther., 2002; 2: 355–378.
13. Chow, Y.H., Huang, W.L., Chi, W.K., Chu, Y.D., Tao. M.H.: Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol., 1997; 71: 169–178.
14. Singh, G., Parker, S., Hobart, P.: The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma. Vaccine, 2002; 20: 1400–1411.
15. Guo, H.C, Liu, Z.X., Sun, S.Q., Leng, Q.W., Li, D., Liu, X.T., Xie, Q.G.: The effect of bovine IFN-α on the immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus. Acta Biochim. Biophys. Sin. (Shanghai), 2004; 36: 701–706.
16. Guo, H., Liu, Z., Sun, S., Bao, H., Chen, Y., Liu, X., Xie, Q.: Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99. Vaccine, 2005; 23: 3236-3242.
17. Cedillo-Barrón, L., Foster-Cuevas, M., Belsham, G.J., Lefèvre, F., Parkhouse, R.M.: Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Virol., 2001; 82: 1713-1724
18. Donnelly, J.J., Ulmer, J.B., Shiver, J.W., Liu, M.A.: DNA vaccines. Annu. Rev. Immunol., 1997; 15: 617–648.
19. Mountford, P.S., Smith, A.G.: Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. Trends Genet., 1995; 11: 179-184.
20. Ghattas. I.R., Sanes, J.R., Majors, J.E.: The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell Biol., 1991; 11: 5848-5859.
21. Molla, A., Jang, S.K., Paul, A.V., Reuer, Q., Wimmer, E.: Cardioviral internal ribosomal entry site is functional in a genetically engineered dicistronic poliovirus. Nature. 1992; 356: 255-257.
22. Wang, C., Sarnow, P., Siddiqui, A.: Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosomebinding mechanism. J. Virol., 1993; 67: 3338-3344.
23. Ramesh, N., Kim, S.T., Wei, M.Q., Khalighi, M., Osborne, W.R.: High-titer bicistronic retroviral vectors employing foot-andmouth disease virus internal ribosome entry site. Nucleic Acids Res.,1996; 24: 2697-2700
24. Sharma, A.K., Khuller, G.K.: DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol. Cell Biol., 2001; 79: 537-546.
25. Hennecke, M., Kwissa, M., Metzger, K., Oumard, A., Kröger, A., Schirmbeck, R., Reimann, J., Hauser, H.: Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res., 2001; 29: 3327–3334.